Industry news

Snapshot: Domain Associates

California’s Biomedical Industry

Brian Halak, Partner, Domain Associates: "We think now is a great time to invest. We believe returns going forward will be high and in the process human health will be improved and jobs will be created."

Russian pharmaceutical market continues to attract foreign investors

The Pharma Letter

Russian Pharmaceutical Industry toward Innovation: moving from "Made in Russia" to "Invented in Russia"

Modern Russia

In the past years, the global pharmaceutical industry has been experiencing a shift in its development: a geographic swing away from the major mature markets, to a set of new dynamics in “pharmerging” countries. The Russian pharmaceutical market is one of these most dynamic and rapidly growing markets.

Pharmaceutical Promotional Spending: Global Trends

Christopher Wooden/ Cegedim Strategic Data

In the twelve-month period to June 2012, industry spending on audited channels came to $90 billion in constant US Dollars with spending in the United States accounting for 32% of the worldwide total. Significant increases in emerging markets ( Brazil +22%, Russia +42% , China +30%) were in marked contrast to cuts in more established markets (USA -6%, EU5 -3.6%). 

Big pharma emerging mkts tactics shift as growth slows

Deena Beasley/ Thomson Reuters

Major pharmaceutical companies aiming to jumpstart growth by investing in emerging markets are reassessing strategies after less-than-stellar results in 2012.  New tactics are expected to include more joint ventures where risks are shared with local partners.

How to invest in Russian startups: An investor’s guide

Adrien Henni, East-West Digital News, VentureBeat.com

As a new generation of startup entrepreneurs is emerging in Russia, the local startup scene tends to look more like its American, European and Asian counterparts. The stereotype of innovative Russian boffins disconnected from market realities, working in Soviet-style research centers, has been replaced by globally connected and modern-minded entrepreneurs and engineers.

Financings of the Fortnight Climbs Half Way To The Stars

The IN ViVO Blog

"...Yeah yeah. We know. The life science venture shakeout isn’t over yet. It’ll get smaller before it gets bigger. Happy new year, everybody. That was the drumbeat we heard as we made the rounds at J.P. Morgan this week."

Venture Capital, Russian Style

Katya Soldak, Forbes

Russia’s scientific community may have experienced a “brain drain” over the past twenty years but the fundamentals of the famous soviet science are still in place, and Putin’s government is revitalizing science-based industry. Betting on nanotechnology, companies can potentially generate substantial returns. Enter Rusnano, a venture capital fund with plans to become a player in the global capital market.

Tough Prescription: Drug Industry Faces Modernization

Irina Filatova, The Moscow Times

Only a fraction of medicines bought in Russia are made here, and Russian drug companies are few. Dragging the pharmaceutical industry into the 21st century will require investment from foreign companies - and from the government, experts say.

Abundant Opportunities within the Russian OTC Market, Invest with Caution when Making the Switch, Suggests Kline

PRNewswire

Russia's rapidly growing over-the-counter market, posting a 12% increase to reach RUB 480 billion (USD 16.4 billion) at the manufacturers' level in 2011, holds much potential for pharmaceutical companies. Although a slight decrease in growth was observed against the previous year, according to new analysis Emerging Markets Rx-to-OTC Switch: Forecasts and Opportunities by global consulting and research firm Kline & Company, the Russian market remains highly robust compared to the U.S. market's 2.4% growth and comparable with the neighboring emerging market of China posting 15.0%.